The clinicians of breastfeeding women diagnosed with postpartum depression must consider the different treatment options for their patients including antidepressants, hormonal therapy, or psychotherapy. In situations where the postpartum depression requires antidepressants, the safety of the nursing infant must be considered. Antidepressants taken during breastfeeding can induce adverse symptoms in the infant. The antidepressants that have been particularly problematic are nefazodone , citalo-pram , doxepin [104, 105], and fluoxetine [106, 107]. Given the negative infant outcomes associated with maternal antidepressant therapies, the US Food and Drug Administration (FDA) has not approved any antidepressant for use during lactation . Alternatively, depression during the postpartum period can impair maternal-infant interactions , which in turn negatively affect infant cognitive development , emotional development , anxiety, and self-esteem . In some cases, the clinician may decide that the potential benefits of maternal antidepressant therapy outweigh the risks in which case paroxetine, sertraline, and nortriptyline should be considered for use first as these have been investigated and are reportedly without adverse infant-related outcomes .
Was this article helpful?
For many years, scientists have been playing out the ingredients that make breast milk the perfect food for babies. They've discovered to day over 200 close compounds to fight infection, help the immune system mature, aid in digestion, and support brain growth - nature made properties that science simply cannot copy. The important long term benefits of breast feeding include reduced risk of asthma, allergies, obesity, and some forms of childhood cancer. The more that scientists continue to learn, the better breast milk looks.